Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Net Margin (2016 - 2025)

Historic Net Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 5.62%.

  • Lifecore Biomedical, Inc. \De\'s Net Margin rose 130800.0% to 5.62% in Q2 2025 from the same period last year, while for May 2025 it was 34.42%, marking a year-over-year decrease of 536200.0%. This contributed to the annual value of 34.42% for FY2025, which is 437900.0% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Net Margin stood at 5.62% for Q2 2025, which was up 130800.0% from 49.44% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Net Margin's 5-year high stood at 47.16% during Q4 2023, with a 5-year trough of 183.73% in Q2 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Net Margin value was 18.27% (recorded in 2022), while the average stood at 34.18%.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Net Margin tumbled by -1790900bps in 2022 and then soared by 1763900bps in 2023.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Net Margin stood at 179.75% in 2021, then surged by 91bps to 16.49% in 2022, then surged by 386bps to 47.16% in 2023, then crashed by -157bps to 26.73% in 2024, then soared by 79bps to 5.62% in 2025.
  • Its Net Margin stands at 5.62% for Q2 2025, versus 49.44% for Q1 2025 and 26.73% for Q4 2024.